NorthWest Biotherapeutics Inc (NWBO)

[f3tt3f]

It's difficult to say.
Depending on how much vaccine they make for each patient (how much tumor is available to lyse) they could have anything between 3-5+ years worth of treatments.

I can't remember if the protocol allows continued treatments after the schedule is complete (apart from progression) but since years' worth of vaccines are manufactured for both arms, any additional manufacturing would either have to come from those who have survived long enough to have exhausted their original supply and still have frozen tumor tissue to create it... or have progressed and have new tumor tissue.

You would hope it were the former, but you couldn't be sure unless you knew the individual patients' enrollment dates and how long their vaccine supply was going to last.
Cognate should have records of when the first batch was manufactured and how many individual treatments they made.
If a patient requires more, Cognate won't know whether they've progressed or not. But they could assume that if they required more at the end of their supply (following scheduled treatment protocol) that the patients have exceeded SOC for OS